Client description: Swiss pharmaceutical company specialising in women’s health
Personas engaged: CEO
A growing pharmaceutical company specialising in pregnancy-related products sought to maintain strong sales of its iron therapeutic, an established reference in Switzerland. The product’s iron content, however, no longer complied with Swiss regulations, triggering a deficiency letter from federal authorities. The client urgently needed a new formula to comply with regulations. Without it, the company risked losing reference for the product and thus an estimated 10% of annual revenue.
Having successfully completed similar projects with SFI Health in the past, the client once again turned to SFI Health for help reformulating the product within the given timeframe.
SFI Health solution
After analysing the new regulations, SFI Health’s product development team reformulated the product to solve the problem. The formula upgrade not only corrected the iron issue, it also included adding state-of-the-art excipients. In addition, SFI helped the client develop a strategic regulatory plan for re-registering the product as an OTC in the Swiss market. After the client approved this new go-to-market strategy, SFI Health’s cross departmental team—including R&D, drug regulatory affairs and project management—worked alongside the client to implement the plan, concluding with the successful submission of the dossier to the health authorities.
SFI Health’s end-to-end capability helped the client maintain the product’s OTC status in the Swiss market. The new formula not only prevented the loss of revenue, it helped the client grow sales by 5% and improve its reputation and credibility in Switzerland.